Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tesaglitazar · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tesaglitazar | DRUG | - |
| Pioglitazone | DRUG | - |
| Dietary and Lifestyle Modification Counseling | BEHAVIORAL | - |
Inclusion Criteria: * Provision of a written informed consent * Men or women who are 30 to 80 years of age * Female patients: postmenopausal or surgically sterile * Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL * Treated with diet alone or treatment with a single oral antidiabet...
Top 16 of 30 competitors
Tesaglitazar was developed as a treatment for Type 2 Diabetes. It is an investigational small molecule that was studied to improve glycemic control in adults with the condition. The drug was tested in a Phase 2 clinical trial but did not advance to later stages of development.
Tesaglitazar targets PPARA and PPARG, which are nuclear receptors involved in lipid and glucose metabolism. It acts as an agonist at both receptors, meaning it activates them. This dual agonist mechanism was intended to improve insulin sensitivity and lipid profiles in people with Type 2 Diabetes.
Tesaglitazar was developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the clinical research program for the drug, including the Phase 2 trial that evaluated its safety and efficacy in Type 2 Diabetes.
Tesaglitazar reached Phase 2 clinical development. It is an investigational drug and is not approved for any indication. The Phase 2 trial has been completed, and there are no active trials of Tesaglitazar listed.
Tesaglitazar was studied in one completed Phase 2 trial, NCT00280865, titled GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes. The trial enrolled 500 participants across the United States, Canada, France, and Mexico.
Yes, Tesaglitazar is also known as AZ 242. The name AZ 242 appears in the title of its Phase 2 clinical trial, NCT00280865, which evaluated the drug in subjects with Type 2 Diabetes. Both names refer to the same investigational compound.